Research Examines Characteristics of Pivotal Trials and FDA Review of Innovative Medical Devices

Patients with serious health conditions who lack sufficient treatment options often look to the U.S. Food and Drug Administration to promptly approve therapeutic alternatives, such as medical devices. Understanding how these innovative devices are developed and approved—including the lengths of premarket clinical trials and FDA review—can help identify ways to get such products to patients more quickly.

Research from The Pew Charitable Trusts, published Feb. 4 in PLOS ONE, examines several years of clinical trial and premarket FDA review data for innovative medical devices that fill unmet needs. The findings indicate that additional work is needed to shorten clinical trials for new products while still ensuring that high-quality data are obtained.

Read the full article.

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.